Glaukos price target raised to $59 from $57 at Citi

Citi analyst Joanne Wuensch raised the firm’s price target on Glaukos to $59 from $57 and keeps a Buy rating on the shares. The analyst "cannot find much fault" in the company’s Q4 results but says the 2023 guidance will likely give investors pause. The firm, however, cites the reset guidance and a new product pipeline including iDose for the Buy rating.